Skip to main content
SpringerLink
Log in

Indikation und Ergebnisse

Apherese-Behandlung bei Lipoprotein(a)-Erhöhungen

  • Fortbildung
  • Schwerpunkt Lipidologie
  • Published:
CardioVasc Aims and scope

Der Gemeinsame Bundesausschuss hat 2008 die Kriterien für eine Apherese-Behandlung bei erhöhtem Lipoprotein(a) definiert. Studien, das Deutsche Lipoproteinapherese-Register und Fallberichte belegen eine hohe Absenkungsrate für kardiovaskuläre Ereignisse (> 80 %) beim Vergleich mit der Situation vor Beginn der Lipoproteinapherese-Therapie. Dabei spielen wahrscheinlich auch pleiotrope Effekte eine Rolle.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Nordestgaard BG, Chapman MJ, Ray K et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844–53

    Article  CAS  Google Scholar 

  2. Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. J Am Coll Cardiol. 2017;69(6):692–711

    Article  CAS  Google Scholar 

  3. Bundesministerium für Gesundheit. Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Richtlinie Methoden vertragsärztliche Versorgung: Apherese bei isolierter Lp(a)-Erhöhung. BAnz 2008;138:3321

  4. Kassenärztliche Bundesvereinigung. Qualitätsbericht 2018, Berichtsjahr 2017. https://www.kbv.de/media/sp/KBV_Qualitaetsbericht_2018.pdf

  5. Jaeger BR, Richter Y, Nagel D et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med. 2009;6(3):229–39

    CAS  PubMed  Google Scholar 

  6. Leebmann J, Roeseler E, Julius U et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation. 2013;128(24):2567–76

    Article  CAS  Google Scholar 

  7. Roeseler E, Julius U, Heigl F et al. Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization. Arterioscler Thromb Vasc Biol. 2016;36(9):2019–27

    Article  CAS  Google Scholar 

  8. Schettler VJJ, Neumann CL, Peter C et al. Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels. Clin Res Cardiol Suppl. 2019;14(Suppl 1):33–38

    Article  CAS  Google Scholar 

  9. Heigl F, Hettich R, Lotz N et al. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany. Atheroscler Suppl. 2015;18:154–62

    Article  Google Scholar 

  10. Schatz U, Tselmin S, Müller G et al. Most significant reduction of cardiovascular events in patients undergoing lipoproteinapheresis due to raised Lp(a) levels - A multicenter observational study. Atheroscler Suppl. 2017;30:246–252

    Article  CAS  Google Scholar 

  11. Safarova MS, Ezhov MV, Afanasieva OI et al. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atheroscler Suppl. 2013;14(1):93–9

    Article  CAS  Google Scholar 

  12. Julius U, Tselmin S, Schatz U et al. Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors. Clin Res Cardiol Suppl. 2019;14(Suppl 1):45–50

    Article  CAS  Google Scholar 

  13. Julius U, Schatz U, Tselmin S et al. Actual situation of Lipoprotein apheresis in patients with elevated Lipoprotein(a) levels. Atheroscler Suppl. 2019; in print

    Article  Google Scholar 

  14. Kronenberg F. Therapeutic lowering of lipoprotein(a): How much is enough? Atherosclerosis. 2019;288:163–165

    Article  CAS  Google Scholar 

  15. Julius U. Current Role of Lipoprotein Apheresis in the Treatment of High-Risk Patients. J Cardiovasc Dev Dis. 2018; https://doi. org/10.3390/jcdd5020027

Download references

Author information

Authors and Affiliations

  1. Lipidologie und Lipoproteinapherese-Zentrum Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl-Gustav-Carus Dresden an der Technischen Universität Dresden, Fetscherstr. 74, 01307, Dresden, Deutschland

    Ulrich Julius

  2. Medizinische Klinik III, Universitätsklinikum Carl-Gustav-Carus Dresden an der Technischen Universität Dresden, Dresden, Deutschland

    Sergey Tselmin,  Ulrike Schatz,  Sabine Fischer &  Stefan Richard Bornstein

Authors
  1. Ulrich Julius
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sergey Tselmin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ulrike Schatz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sabine Fischer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Stefan Richard Bornstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ulrich Julius.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Julius, U., Tselmin, S., Schatz, U. et al. Apherese-Behandlung bei Lipoprotein(a)-Erhöhungen. CV 19, 35–38 (2019). https://doi.org/10.1007/s15027-019-1673-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15027-019-1673-3

Search

Navigation